Biogen Inc (BUE:BIIB)
ARS 18434.5 -134.5 (-0.72%) Market Cap: 28.46 Til Enterprise Value: 33.64 Til PE Ratio: 27.65 PB Ratio: 2.11 GF Score: 53/100

SAGE Therapeutics Inc Conference Call to Discuss Collaboration with Biogen Inc Transcript

Nov 30, 2020 / 01:00PM GMT
Release Date Price: ARS2850 (+1.08%)
Operator

Good morning, and welcome to Sage Therapeutics conference call. (Operator Instructions) This call is being webcast live on the Investor and Media section of Sage's website at sagerx.com. This call is the property of Sage Therapeutics and recording, reproduction or transmission of this call without the expressed written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.

I would now like to introduce Jeff Boyle, Head of Investor Relations at Sage.

Jeff Boyle
Sage Therapeutics, Inc. - Investor Contact

Good morning, and thank you for joining Sage's conference call to discuss our strategic collaboration with Biogen. Before we begin, I encourage everyone to go to the Investors and Media section of our website at sagerx.com, where you can find the press release related to today's call.

Let me first point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot